# Study of Magrolimab in Patients With Solid Tumors

> **NCT04827576** · PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 106 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Magrolimab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT04827576
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-01
- **Primary completion:** 2024-10-01
- **Final completion:** 2024-10-01
- **Target enrollment:** 106 (ACTUAL)
- **Why stopped:** Sponsor decision to terminate study
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04827576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04827576, "Study of Magrolimab in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04827576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*